Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IGM Biosciences Inc (IGMS)
NASDAQ:IGMS
Holding IGMS?
Track your performance easily
IGMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.81 - $22.50
Previous Close$16.65
Volume380.04K
Average Volume (3M)310.43K
Market Cap
$987.66M
Enterprise Value$770.65M
Total Cash (Recent Filing)$256.38M
Total Debt (Recent Filing)$39.37M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Nov 07, 2024EPS Estimate
-$0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding59,318,669
10 Day Avg. Volume437,329
30 Day Avg. Volume310,430
Standard Deviation0.29
R-Squared0.00103
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.08
Price to Sales (P/S)360.27
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.68K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.51
Forecast
1Y Price Target
$18.43Price Target Upside6.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
IGM Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsIGM Biosciences reported positive enrollment updates across its clinical pipeline.
Financial PerformanceIGM ended 2Q24 with ~$256.4M in cash; this balance sheet strength is expected to provide an operational runway into 2Q26.
Product DevelopmentManagement has initiated a new trial for Imvotamab in idiopathic inflammatory myopathies.
Bears Say
EarningsIGM Biosciences recorded a net loss of $0.79 per share—significantly wider than the original estimated net gain of $0.21 per share; the difference is attributed to lower-than-anticipated collaboration revenue.
Financial PerformanceIGM currently expects a full-year 2024 GAAP operating expense range of $210-220M, including $40M in stock-based compensation.
RisksRisks include inability to achieve a best-in-class profile for IGM-8444, failure to obtain approval for IGM-8444 or imvotamab, setbacks with other candidates, inability to achieve competitive manufacturing efficiencies with IgM-based antibodies, and medium to long-term dilution risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IGMS FAQ
What was IGM Biosciences Inc’s price range in the past 12 months?
IGM Biosciences Inc lowest stock price was $3.81 and its highest was $22.50 in the past 12 months.
What is IGM Biosciences Inc’s market cap?
Currently, no data Available
When is IGM Biosciences Inc’s upcoming earnings report date?
IGM Biosciences Inc’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were IGM Biosciences Inc’s earnings last quarter?
IGM Biosciences Inc released its earnings results on Aug 14, 2024. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.041 by -$0.749.
Is IGM Biosciences Inc overvalued?
According to Wall Street analysts IGM Biosciences Inc’s price is currently Undervalued.
Does IGM Biosciences Inc pay dividends?
IGM Biosciences Inc does not currently pay dividends.
What is IGM Biosciences Inc’s EPS estimate?
IGM Biosciences Inc’s EPS estimate is -$0.79.
How many shares outstanding does IGM Biosciences Inc have?
IGM Biosciences Inc has 33,931,686 shares outstanding.
What happened to IGM Biosciences Inc’s price movement after its last earnings report?
IGM Biosciences Inc reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.041. Following the earnings report the stock price went down -1.802%.
Which hedge fund is a major shareholder of IGM Biosciences Inc?
Among the largest hedge funds holding IGM Biosciences Inc’s share is Baker Bros Advisors LP. It holds IGM Biosciences Inc’s shares valued at 28M.
---
IGM Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.43 (6.96% Upside)
$18.43 (6.96% Upside)
Blogger Sentiment
Neutral
IGMS Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 916.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $130.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 5.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
129.97%
12-Months-Change
Fundamentals
Return on Equity
-115.71%
Trailing 12-Months
Asset Growth
-29.99%
Trailing 12-Months
Company Description
IGM Biosciences Inc
IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.
---
IGMS Earnings Call
Q4 2023
0:00 / 0:00
---
IGMS Stock 12 Month Forecast
Average Price Target
$18.43
▲(6.96% Upside)
Technical Analysis
Best Analysts Covering IGMS
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+55.43%
reiterated a buy rating yesterday
Copying Stephen Willey's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +55.43% per trade.
---